Diligence memo · auto-generated · as of July 2, 2026
Fairfield Bio, Inc.
Fairfield Bio, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Fairfield Bio, Inc. operates in Biotech / Pharma, based in BRONX.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Fairfield Bio, Inc. has raised $450K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $450K on 2026-01-26.
Most recent recorded round closed around 2026-01-26.
Valuation (modeled)modeled
Provath models Fairfield Bio, Inc. at approximately $797K (range $246K–$1.7M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.95× the median modeled value of Pre-Seed Biotech / Pharma companies in 2025–2027 (6 peers) — value vs value, same stage and era. Within the normal band (95% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 5 mo ago; this sector typically re-raises about every 15 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 22% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 8% of those peers.
Closest niche peers: Cosmos Pharmaceuticals, LLC, Stratum Biosciences Inc., Amptiv Biosciences, Inc., Gaingels Aether Bio 2025 LLC, Gaingels Glyphic Bio 2025 LLC.
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.